Sarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Sarepta (SRPT) Bullish View Reiterated at Credit Suisse at EXONDYS51 Gains Momentum
April 28, 2017 6:45 AM EDTCredit Suisse analyst Alethia Young reiterated an Outperform rating and $64 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the company raised guidance to $95M from $80M as the launch continues to look "highly encouraging"
The firm's new 2017 estimate is $103M, up... More
Sarepta Therapeutics (SRPT) Misses Q1 EPS by 24c, Revenue Beats
April 27, 2017 4:11 PM EDTSarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($0.60), $0.24 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $16.3 million versus the consensus estimate of $13.86 million.
Company anticipates net revenues for the year will exceed $95 million
(Street sees FY rev... More
